Topical Tranexamic Acid for Bilateral Breast Reduction Surgery
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Hematoma is a common complication of bilateral breast reduction (BBR) surgery. This can lead
to pain and discomfort experienced by the patient, in addition to greater use of valuable
healthcare resources. Previous studies have shown correlation between the use of tranexamic
acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events.
In this randomized control trial (RCT) evaluation TXA use in BBR, for which one breast will
be randomized to have TXA applied topically, while the other will have normal saline (NS)
placebo applied. The primary objective of this prospective blinded randomized control trial
study is to determine if the administration of topical TXA in BBR reduces the incidence of
surgical site hematoma compared to placebo within 2 weeks following surgery. The results of
this study will be used to inform the design of a larger multicentered RCT on TXA in breast
surgery.